Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
about
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular diseaseRole of neurons and glia in the CNS actions of the renin-angiotensin system in cardiovascular controlFluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditionsTreatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortasFluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2.Regulation of oxidative stress and cardioprotection in diabetes mellitus.Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxiaActivation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.Emerging translational approaches to target STAT3 signalling and its impact on vascular diseasePharmacological basis of different targets for the treatment of atherosclerosis.Role of angiotensin II receptor blockers in atherosclerotic plaque stability.The Establishment and Characteristics of Rat Model of Atherosclerosis Induced by HyperuricemiaStatins: another class of antihypertensive agents?New anti-inflammatory agents to reduce atherosclerosis.A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat heartsAng II-stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice.Vascular endothelial growth factor in eye disease.The antihypertensive actions of statins: modulation by salt intake.A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.Anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway.A new systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts overall and cardiovascular mortality in hemodialysis patients.Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease.Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.Cuff-induced vascular intima thickening is influenced by titration of the Ace gene in mice.Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells.Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs
P2860
Q26750725-115D9520-3727-4125-B479-06A99A034F35Q28081615-AB79E5DE-06B4-49DD-8021-2E692D93578EQ28568345-FD17EBB4-677F-4D18-B619-F2D7BF179952Q28577025-4E9983D6-36B2-47CA-8B0E-BB0480933282Q33316547-8EF4FF25-EF4B-478D-984A-144A8B9ED3B1Q33572259-219A48F9-4B6E-4970-BF74-7CACEE424B9AQ34208940-D01537C0-D592-482D-AC75-C7E749FB2A04Q34360215-82C26180-E2B6-4BDE-92FC-C2C7F292FDE3Q35580177-5F008362-9F7D-47A2-AB40-BBDD70F5D0FFQ36346487-37D993A1-5090-41FD-AFD6-5A4D68BB4538Q36382568-380C0A0D-0B8D-4E42-8D27-B13C0E0BBA86Q36405350-E50559FC-AD60-4E96-85C8-0933EE74730BQ36411099-73608AB2-E51E-4A14-A002-C415AA6BFCC1Q36576558-2F6F649C-C3C5-48DB-87E8-20CC7917809DQ36577081-3DE226C4-5C5F-4BE9-8866-09107E3F4898Q36749726-17E25648-205C-452C-8850-3E86E21FFEB6Q36929380-3339EB4D-6311-490B-85A7-645840D35EF8Q38029526-985DDFF4-C0ED-4633-9D96-E1F9DC711DDEQ42180663-36E17FC8-6AA8-4B9C-9868-B0B383FBAA49Q42725443-5146204C-3D25-492A-8882-79A8FE0D7DABQ43142479-3707E911-20EA-4FA9-BD3B-1F993A03D701Q44477930-7D2D7AB1-FF37-410C-8E15-C32EBA846755Q44695239-A646F095-34C3-4AFA-B027-E7E88CA4536BQ45282263-2E653D6E-F6F6-443E-8D2E-27860AC68A23Q45991482-02E7284B-B67B-4BE1-8FE5-BC18C8210050Q46064003-F0B66A3F-BF64-41F0-B202-D68CCCE150FDQ46101812-FBC8FC8C-161C-499E-A627-18252F8F038CQ46921390-5DCDD145-BC87-43E0-A1F8-39BBB93855B8Q57072670-CE7C2366-F110-4851-A0D5-C9DDA282FDF8
P2860
Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@en
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@nl
type
label
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@en
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@nl
prefLabel
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@en
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@nl
P2093
P1433
P1476
Fluvastatin enhances the inhib ...... vascular neointimal formation.
@en
P2093
Jian-Mei Li
Masaru Iwai
Masatsugu Horiuchi
P304
P356
10.1161/01.CIR.0000043244.13596.20
P407
P577
2003-01-01T00:00:00Z